Article Sidebar

PDF (Tiếng Việt)
Published: 2026-03-09
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v199i2.4614
Issue
Vol. 199 No. 2 (2026)
Section
Các bài báo
How to Cite
Linh, L. T. M., Hân, N. N. V., Đề, P. N., Khoan, L. T., & Tuấn, H. X. (2026). The diagnostic value of PI-RADS version 2.1 On multiparametric magnetic resonance imaging combined with prostate-specific antigen in the diagnosis of prostate cancer. Journal of Medical Research, 199(2), 179-188. https://doi.org/10.52852/tcncyh.v199i2.4614

The diagnostic value of PI-RADS version 2.1 On multiparametric magnetic resonance imaging combined with prostate-specific antigen in the diagnosis of prostate cancer

Le Thi My Linh, Nguyen Ngoc Vinh Han, Pham Ngoc De, Le Trong Khoan, Ho Xuan Tuan

Main Article Content

Abstract

Prostate cancer is a leading malignancy in men. The application of the Prostate Imaging Reporting and Data System (PI-RADS) 2.1 on multiparametric MRI (mpMRI) is critical for diagnosis and management. This cross-sectional study included 46 patients with suspected prostate cancer at Hue University of Medicine and Pharmacy Hospital and Da Nang Oncology Hospital (May 2024 - May 2025). All patients underwent mpMRI, PSA testing, and histopathological evaluation. Diagnostic performance was analyzed using ROC curves and R software version 4.5.0. Results indicated that total PSA and PSA density were significantly higher in the prostate cancer group (p < 0.001). PI-RADS 2.1 demonstrated high diagnostic performance (AUC = 0.933). Malignancy rates increased significantly with higher PI-RADS scores (p < 0.001). A biopsy threshold of PI-RADS ≥ 4 avoided 52.2% of unnecessary biopsies, with a specificity of 85.2% and sensitivity of 94.7%. In conclusion, the PI-RADS version 2.1 system on multiparametric MRI demonstrates supportive diagnostic value in the detection of prostate cancer and has the potential to contribute to reducing unnecessary biopsy indications.

Article Details

Keywords

prostate cancer, PI-RADS 2.1, multiparametric magnetic resonance imaging (mpMRI), biopsy decision

References

1. Li Y, Wang S, Wang J, et al. PI-RADSv2.1 combined with PSA density for optimizing prostate biopsy decisions: a retrospective analysis. Frontiers in oncology. 2025;15:1602412. doi:http://doi.org/10.3389/fonc.2025.1602412
2. Eklund M, Jäderling F, Discacciati A, et al. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. The New England journal of medicine. 2021;385(10):908-920. doi:http://doi.org/10.1056/NEJMoa2100852
3. Scott R, Misser SK, Cioni D, et al. PI-RADS v2.1: What has changed and how to report. SA journal of radiology. 2021;25(1):2062. doi:http://doi.org/10.4102/sajr.v25i1.2062
4. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European urology. 2019;76(3):340-351. doi:http://doi.org/10.1016/j.eururo.2019.02.033
5. Park KJ, Choi SH, Kim MH, et al. Performance of Prostate Imaging Reporting and Data System Version 2.1 for Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of magnetic resonance imaging : JMRI. 2021;54(1):103-112. doi:http://doi.org/10.1002/jmri.27546
6. Oerther B, Engel H, Bamberg F, et al. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate cancer and prostatic diseases. 2022;25(2):256-263. doi:http://doi.org/10.1038/s41391-021-00417-1
7. Trương Thị Thanh, Hoàng Đình Âu. Giá trị của cộng hưởng từ trong chẩn đoán các nhân vùng chuyển tiếp tuyến tiền liệt theo PIRADS 2.1. Tạp chí Y học Việt Nam. 2023;522(2):160-163. doi:http://doi.org/10.51298/vmj.v522i2.4339
8. Vương Thị Hà Ngân, Trần Quang Hiền, Lê Anh Thành, và cs. Vai trò của PI-RADS phiên bản 2.1 trên cộng hưởng từ trong chẩn đoán ung thư tiền liệt tuyến. Tạp chí Y học Việt Nam. 2024;533(2):404-407. doi:http://doi.org/10.51298/vmj.v533i2.8002
9. Võ Thị Thúy Hằng, Võ Tấn Đức, Đỗ Hải Thanh Anh, và cs. Đối chiếu tổn thương PI-RADS phiên bản 2 trên cộng hưởng từ với kết quả mô bệnh học. Tạp chí Y học Thành phố Hồ Chí Minh. 2021;25(1):9-13. doi:https://tapchiyhoctphcm.vn/articles/17936
10. Yamaya N, Kimura K, Ichikawa R, et al. Prospective evaluation of PI-RADSv2.1 using multiparametric and biparametric MRI for detecting clinically significant prostate cancer based on MRI/US fusion-guided biopsy. Japanese journal of radiology. 2025;43(3):472-482. doi:http://doi.org/10.1007/s11604-024-01675-4
11. Gao C, Li Y, Hu C, et al. The significance of PI-RADS v2.1 score combined with quantitative parameters of DWI and DCE-MRI in differentiating between benign prostatic hyperplasia and prostate cancer. Journal of Men’s Health. 2024;20(9):95-102. doi:http://doi.org/10.22514/jomh.2024.154
12. Kim CK. Prostate Imaging Reporting and Data System (PI-RADS) v 2.1: Overview and Critical Points. Journal of the Korean Society of Radiology. 2023;84(1):75-91. doi:http://doi.org/10.3348/jksr.2022.0169
13. Pellegrino F, Tin AL, Martini A, et al. Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? European urology focus. 2023;9(2):291-297. doi:http://doi.org/10.1016/j.euf.2022.10.002
14. Peng Y, Wei C, Li Y, et al. Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings. BMC urology. 2025;25(1):42. doi:http://doi.org/10.1186/s12894-025-01719-5
15. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. The New England journal of medicine. 2018;378(19):1767-1777. doi:http://doi.org/doi:10.1056/NEJMoa1801993